SCHEMBL3673097

SCHEMBL3673097

COC(=O)CCn1cc(-c2ccc3[nH]nc(N)c3c2)cn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 10/20 0.48
GSK3B P49841 9/20 0.48
JAK2 O60674 5/20 0.46
KDR P35968 4/20 0.46
PRMT5 O14744 2/20 0.44
WDR77 Q9BQA1 2/20 0.44
PLK4 O00444 1/20 0.44
DAPK3 O43293 1/20 0.44
DYRK3 O43781 1/20 0.44
ROCK2 O75116 1/20 0.44
MAP4K4 O95819 1/20 0.44
CDK1 P06493 1/20 0.44
RPS6KB1 P23443 1/20 0.44
CDK2 P24941 1/20 0.44
MARK3 P27448 1/20 0.44
TYK2 P29597 1/20 0.44
CLK2 P49760 1/20 0.44
GSK3A P49840 1/20 0.44
JAK3 P52333 1/20 0.44
LIMK1 P53667 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3664589 0.87 PRMT5 (0.47) DYRK1AGSK3BJAK2KDRPRMT5
SCHEMBL3673700 0.80 KDR (0.52) DYRK1AGSK3BJAK2KDRPRMT5
SCHEMBL16516847 0.79 GSK3B (0.53) DYRK1AGSK3BPRMT5WDR77
SCHEMBL3809766 0.77 GSK3B (0.49) DYRK1AGSK3BJAK2KDRPRMT5
SCHEMBL4292031 0.77 JAK2 (0.47) DYRK1AGSK3BJAK2KDRPRMT5
SCHEMBL2660282 0.75 AXL (0.65) DYRK1AGSK3BJAK2PRMT5WDR77
SCHEMBL3673303 0.74 JAK2 (0.49) DYRK1AGSK3BJAK2KDRPRMT5
SCHEMBL4287714 0.74 CDC7 (0.67) DYRK1AGSK3BJAK2KDRPLK4
SCHEMBL16516824 0.73 PRMT5 (0.55) DYRK1AGSK3BPRMT5WDR77
SCHEMBL18563593 0.72 HPGD (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US claimed
CN-101790526-A 5-heteroaryl substituted indazoles as kinase inhibitors ABBOTT GMBH & CO KG 2010-07-28 CN claimed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US claimed
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
CN-101790526-A 5-heteroaryl substituted indazoles as kinase inhibitors ABBOTT GMBH & CO KG 2010-07-28 CN disclosed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 DYRK1A 276/4885GSK3B 1/4885JAK2 102/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 DYRK1A 276/4885GSK3B 1/4885JAK2 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.